Download PDF
Hamostaseologie 2020; 40(02): 226-232
DOI: 10.1055/a-1141-1252
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Perinatal Management of Haemophilia

Werner Streif
1   Medizinische Universität Innsbruck (MUI), Department für Kinder- und Jugendheilkunde, Pädiatrie 1, Innsbruck, Austria
,
Ralf Knöfler
2   Universitätsklinikum Dresden Klinik/Poliklinik für Kinder- und Jugendmedizin Bereich Hämatologie, Dresden, Germany
› Author Affiliations
Further Information

Publication History

04 November 2019

18 March 2020

Publication Date:
28 May 2020 (online)

Also available at
   Permissions and Reprints

Abstract

The aim of this review is to provide practical guidance for the treatment of carriers of haemophilia and newborns presenting with haemophilia. Both mother and newborn have an increased risk for clinically relevant bleeding. An experienced team should manage genetic counselling, prenatal diagnosis, pregnancy, delivery and the newborn presenting with haemophilia. Published and regularly updated guidelines must guide this team. Vaginal and caesarean deliveries before labour entail a comparable bleeding risk. Haemophilia carriers should receive factor concentrate (FC) at the time of delivery if their factor level is below normal. Evidence remains insufficient to recommend systemic desmopressin and tranexamic acid for the prevention of peripartum haemorrhage. Primary prophylaxis with FC for all newborns with severe haemophilia is not justified. The pattern of bleeding seen in the affected newborns is essentially different from that seen in older children. Estimated frequency of intracranial haemorrhage (ICH) is 2 to 3%. Cranial ultrasound is a good screening method for ICH in newborns. Many neonatal bleeds are iatrogenic in origin. The most prominent concerns regarding neonatal factor replacement are the risk for inhibitor development, followed by local bleeding and issues related to poor vascular access. The preference for plasma-derived FC and recombinant FC differs widely between centres and countries. Replacement therapy should be monitored since newborns may require higher doses of FC. Emicizumab, licensed for all age groups since 2019, should not be used in newborns with severe haemophilia A and acute bleeding, although “non-factor” agents are expected to revolutionise haemophilia therapy.

Zusammenfassung

Ziel dieser Übersicht ist eine praktische Anleitung zum Umgang mit Überträgerinnen von Hämophilie (Konduktorinnen) und Neugeborenen mit Hämophilie zu geben. Sowohl Konduktorinnen als auch betroffene Nachkommen haben ein relevant erhöhtes Blutungsrisiko. Nur ein erfahrenes Team sollte genetische Beratung, Pränatal diagnostik, Schwangerschaft, Geburt und das betroffene Neugeborene betreuen. Publizierte und regelmäßig aktualisierte Leit- und Richtlinien müssen immer die Grundlage des Handelns sein. Die vaginale Entbindung und der elektive Kaiserschnitt haben ein vergleichbares Blutungsrisiko. Für Konduktorinnen, die bei der Geburt einen Faktorspiegel unter dem Normalwert aufweisen, sind Faktorkonzentrate empfohlen. Die Wirksamkeit von Desmopressin und Tranexamsäure zur Behandlung peri- und postpartaler Blutungen ist nicht gesichert. Eine primäre Prophylaxe mit Faktorkonzentraten aller Neugeborenen mit schwerer Hämophilie ist nicht gerechtfertigt. Blutungen des Neugeborenen unterscheiden sich grundsätzlich von denen des älteren Kindes. In 2 bis 3% treten intrakranielle Blutungen auf. Die Ultraschalluntersuchung ist eine gute Suchmethode zum Ausschluss einer intrakraniellen Blutung beim Neugeborenen. Viele Blutungen werden erst durch medizinische Manipulationen verursacht. Die größten Bedenken gegen eine frühe Behandlung mit Faktorenkonzentraten von hämophilen Neugeborenen sind die Entwicklung eines Hemmkörpers gegen FVIII/ IX, lokale Blutungskomplikationen und der problematische venöse Zugang. Unterschiedlich nach Land und Zentrum werden bevorzugt aus Plasma hergestellte oder rekombinante Faktorkonzentrate verabreicht. Bei jeder Faktorgabe sollte der Faktorspiegel überwacht werden, da Neugeborene mehr Faktor benötigen können als ältere Kinder. Zurzeit wird von der Verwendung von Emicizumab, das seit 2019 für alle Altersgruppen zugelassen ist, für Neugeborene mit schwerer Hämophilie A und akuter Blutung abgeraten, auch wenn zu erwarten ist, dass “non-factor” Medikamente die Behandlung der Hämophilie revolutionieren werden.

Keywords

haemophilia - pregnancy - bleeding disorders

Schlüsselwörter

Hämophilie - Schwangerschaft - Blutungsrisiko
 

  • References

  • 1 Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH. , et al. Bleeding in carriers of hemophilia. Blood 2006; 108 (01) 52-56
    PubMedGoogle Scholar
  • 2 Pabinger I, Heistinger M, Muntean W. , et al. Treatment of haemophilia in Austria [in German]. Wien KlinWochenschr 2015; 127 (Suppl. 03) S115-S130
    PubMedGoogle Scholar
  • 3 Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M. ; Paediatric Working Party of United Kingdom Haemophilia Doctors' Organization. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154 (02) 208-215
    CrossrefPubMedGoogle Scholar
  • 4 Schlembach D, Helmer H, Henrich W. , et al. Peripartum haemorrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). GeburtshilfeFrauenheilkd 2018; 78 (04) 382-399
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Harton GL, Magli MC, Lundin K, Montag M, Lemmen J, Harper JC. ; European Society for Human Reproduction and Embryology (ESHRE) PGD Consortium/Embryology Special Interest Group. ESHRE PGD Consortium/Embryology Special Interest Group--best practice guidelines for polar body and embryo biopsy for preimplantation genetic diagnosis/screening (PGD/PGS). Hum Reprod 2011; 26 (01) 41-46
    CrossrefPubMedGoogle Scholar
  • 6 Beta J, Zhang W, Geris S, Kostiv V, Akolekar R. Procedure-related risk of miscarriage following chorionic villus sampling and amniocentesis. Ultrasound ObstetGynecol 2019; 54 (04) 452-457
    PubMedGoogle Scholar
  • 7 James AH, Konkle BA, Kouides P. , et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015; 21 (01) 81-87
    CrossrefPubMedGoogle Scholar
  • 8 Yang MY, Ragni MV. Clinical manifestations and management of labor and delivery in women with factor IX deficiency. Haemophilia 2004; 10 (05) 483-490
    CrossrefPubMedGoogle Scholar
  • 9 Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia 2008; 14 (01) 56-64
    PubMedGoogle Scholar
  • 10 Dunkley S, Curtin JA, Marren AJ, Heavener RP, McRae S, Curnow JL. Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy. Med J Aust 2019; 210 (07) 326-332
    CrossrefPubMedGoogle Scholar
  • 11 Streif W, Knöfler R, Eberl W. , et al; Paediatric Committee of the Society of Thrombosis and Haemostasis Research. Therapy of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e. V.) [in German]. Hamostaseologie 2014; 34 (04) 269-275 , quiz 276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Knöfler R, Koscielny J, Tauer JT. , et al. Desmopressin testing in haemophilia A patients and carriers: results of a multicentre survey. Hamostaseologie 2012; 32 (04) 271-275
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev 2019; 2: CD009824
    PubMedGoogle Scholar
  • 14 Pabinger I, Fries D, Schöchl H, Streif W, Toller W. Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis. Wien KlinWochenschr 2017; 129 (9–10): 303-316
    PubMedGoogle Scholar
  • 15 Collaborators WT. ; WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
    CrossrefPubMedGoogle Scholar
  • 16 Sentilhes L, Winer N, Azria E. , et al; Groupe de Recherche enObstétrique et Gynécologie. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med 2018; 379 (08) 731-742
    CrossrefPubMedGoogle Scholar
  • 17 Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341 (23) 1709-1714
    CrossrefPubMedGoogle Scholar
  • 18 Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz-Körholz C, Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs--a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 1999; 158 (Suppl. 03) S162-S165
    CrossrefPubMedGoogle Scholar
  • 19 Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007; 13 (04) 380-382
    CrossrefPubMedGoogle Scholar
  • 20 Andersson NG, Auerswald G, Barnes C. , et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol 2017; 179 (02) 298-307
    CrossrefPubMedGoogle Scholar
  • 21 Andersson NG, Chalmers EA, Kenet G, Ljung R, Mäkipernaa A, Chambost H. ; PedNet Haemophilia Research Foundation. Mode of delivery in hemophilia: vaginal delivery and cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica 2019; 104 (10) 2100-2106
    CrossrefPubMedGoogle Scholar
  • 22 Karanth L, Kanagasabai S, Abas AB. Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers. Cochrane Database Syst Rev 2017; 8: CD011059
    PubMedGoogle Scholar
  • 23 Mibashan RS, Rodeck CH, Thumpston JK. , et al. Plasma assay of fetal factors VIIIC and IX for prenatal diagnosis of haemophilia. Lancet 1979; 1 (8130): 1309-1311
    PubMedGoogle Scholar
  • 24 Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J ThrombHaemost 2018; 16 (10) 2106-2110
    CrossrefPubMedGoogle Scholar
  • 25 Andrew M, Paes B, Milner R. , et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (01) 165-172
    CrossrefPubMedGoogle Scholar
  • 26 Nagel K, Pai MK, Paes BA, Chan AK. Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagul Fibrinolysis 2013; 24 (01) 23-27
    CrossrefPubMedGoogle Scholar
  • 27 Bidlingmaier C, Bergmann F, Kurnik K. Haemophilia A in two premature infants. Eur J Pediatr 2005; 164 (02) 70-72
    CrossrefPubMedGoogle Scholar
  • 28 Ben Chaim J, Livne PM, Binyamini J, Hardak B, Ben-Meir D, Mor Y. Complications of circumcision in Israel: a one yearmulticenter survey. Isr Med Assoc J 2005; 7 (06) 368-370
    PubMedGoogle Scholar
  • 29 Kearney S, Sharathkumar A, Rodriguez V. , et al. Neonatal circumcision in severe haemophilia: a survey of paediatric haematologists at United States hemophilia treatment centers. Haemophilia 2015; 21 (01) 52-57
    CrossrefPubMedGoogle Scholar
  • 30 Wezel-Meijler Gv, de Vries LS. Cranial ultrasound - optimizing utility in the NICU. CurrPediatr Rev 2014; 10 (01) 16-27
    PubMedGoogle Scholar
  • 31 Elkhunovich M, Sirody J, McCormick T, Goodarzian F, Claudius I. The utility of cranial ultrasound for detection of intracranial hemorrhage in infants. PediatrEmerg Care 2018; 34 (02) 96-101
    PubMedGoogle Scholar
  • 32 Hong HS, Lee JY. Intracranial hemorrhage in term neonates. Childs NervSyst 2018; 34 (06) 1135-1143
    PubMedGoogle Scholar
  • 33 Peyvandi F, Mannucci PM, Garagiola I. , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophiliaA. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 34 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
    CrossrefPubMedGoogle Scholar
  • 35 Guilcher GM, Scully MF, Harvey M, Hand JP. Treatment of intracranial and extracranial haemorrhages in a neonate with severe haemophilia B with recombinant factor IX infusion. Haemophilia 2005; 11 (04) 411-414
    CrossrefPubMedGoogle Scholar
  • 36 Maeda T, Sasabuchi Y, Matsui H, Ohnishi Y, Miyata S, Yasunaga H. Safety of tranexamic acid in pediatric cardiac surgery: a nationwide database study. J CardiothoracVascAnesth 2017; 31 (02) 549-553
    PubMedGoogle Scholar
  • 37 Pierce GF, Hart DP, Kaczmarek R. ; Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH). Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia 2019; 25 (05) e334-e335
    CrossrefPubMedGoogle Scholar